nodes	percent_of_prediction	percent_of_DWPC	metapath
Drospirenone—PTGS2—glaucoma	0.318	1	CbGaD
Drospirenone—BCHE—Echothiophate—glaucoma	0.213	0.384	CbGbCtD
Drospirenone—BCHE—Physostigmine—glaucoma	0.213	0.384	CbGbCtD
Drospirenone—BCHE—Dipivefrin—glaucoma	0.129	0.233	CbGbCtD
Drospirenone—NR3C2—ACE Inhibitor Pathway—MAS1—glaucoma	0.00618	0.154	CbGpPWpGaD
Drospirenone—NR3C2—ACE Inhibitor Pathway—ACE2—glaucoma	0.00468	0.117	CbGpPWpGaD
Drospirenone—Embolism—Latanoprost—glaucoma	0.0034	0.041	CcSEcCtD
Drospirenone—Loss of libido—Clonidine—glaucoma	0.00234	0.0282	CcSEcCtD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—POU4F2—glaucoma	0.00227	0.0566	CbGpPWpGaD
Drospirenone—Thrombosis—Pilocarpine—glaucoma	0.00191	0.023	CcSEcCtD
Drospirenone—Cerebrovascular accident—Carteolol—glaucoma	0.00184	0.0222	CcSEcCtD
Drospirenone—Cerebrovascular accident—Levobunolol—glaucoma	0.00174	0.021	CcSEcCtD
Drospirenone—Breast pain—Pilocarpine—glaucoma	0.00155	0.0187	CcSEcCtD
Drospirenone—Acute coronary syndrome—Metipranolol—glaucoma	0.00148	0.0179	CcSEcCtD
Drospirenone—Myocardial infarction—Metipranolol—glaucoma	0.00147	0.0178	CcSEcCtD
Drospirenone—Depression—Carteolol—glaucoma	0.00139	0.0168	CcSEcCtD
Drospirenone—Thrombosis—Betaxolol—glaucoma	0.00133	0.016	CcSEcCtD
Drospirenone—Depression—Levobunolol—glaucoma	0.00131	0.0158	CcSEcCtD
Drospirenone—PTGS2—Prostaglandin Synthesis and Regulation—ANXA3—glaucoma	0.00126	0.0315	CbGpPWpGaD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—POU4F1—glaucoma	0.00124	0.031	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—PITX2—glaucoma	0.00123	0.0307	CbGpPWpGaD
Drospirenone—Nausea—Physostigmine—glaucoma	0.00119	0.0144	CcSEcCtD
Drospirenone—Erythema multiforme—Levobunolol—glaucoma	0.00112	0.0135	CcSEcCtD
Drospirenone—Breast pain—Betaxolol—glaucoma	0.00108	0.013	CcSEcCtD
Drospirenone—Erythema multiforme—Methazolamide—glaucoma	0.00107	0.0129	CcSEcCtD
Drospirenone—Cerebrovascular accident—Dorzolamide—glaucoma	0.00106	0.0128	CcSEcCtD
Drospirenone—NR3C2—ACE Inhibitor Pathway—NOS3—glaucoma	0.00103	0.0257	CbGpPWpGaD
Drospirenone—Affect lability—Dorzolamide—glaucoma	0.00102	0.0123	CcSEcCtD
Drospirenone—Mood swings—Dorzolamide—glaucoma	0.000984	0.0119	CcSEcCtD
Drospirenone—Affect lability—Pilocarpine—glaucoma	0.000966	0.0116	CcSEcCtD
Drospirenone—Migraine—Pilocarpine—glaucoma	0.000966	0.0116	CcSEcCtD
Drospirenone—Depression—Bimatoprost—glaucoma	0.000944	0.0114	CcSEcCtD
Drospirenone—Mood swings—Pilocarpine—glaucoma	0.000929	0.0112	CcSEcCtD
Drospirenone—Breast disorder—Brinzolamide—glaucoma	0.000923	0.0111	CcSEcCtD
Drospirenone—Haemorrhage—Apraclonidine—glaucoma	0.000876	0.0106	CcSEcCtD
Drospirenone—PTGS2—Prostaglandin Synthesis and Regulation—PTGFR—glaucoma	0.000862	0.0215	CbGpPWpGaD
Drospirenone—Depression—Brimonidine—glaucoma	0.000835	0.0101	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Latanoprost—glaucoma	0.000807	0.00973	CcSEcCtD
Drospirenone—Cerebrovascular accident—Clonidine—glaucoma	0.0008	0.00964	CcSEcCtD
Drospirenone—Depression—Dorzolamide—glaucoma	0.000798	0.00962	CcSEcCtD
Drospirenone—Angiopathy—Apraclonidine—glaucoma	0.000795	0.00959	CcSEcCtD
Drospirenone—Depression—Travoprost—glaucoma	0.000794	0.00958	CcSEcCtD
Drospirenone—Acute coronary syndrome—Dorzolamide—glaucoma	0.000789	0.00951	CcSEcCtD
Drospirenone—Depression—Brinzolamide—glaucoma	0.000784	0.00946	CcSEcCtD
Drospirenone—Myocardial infarction—Dorzolamide—glaucoma	0.000784	0.00946	CcSEcCtD
Drospirenone—Angiopathy—Bimatoprost—glaucoma	0.000771	0.00929	CcSEcCtD
Drospirenone—Mental disorder—Apraclonidine—glaucoma	0.000768	0.00926	CcSEcCtD
Drospirenone—Nervous system disorder—Latanoprost—glaucoma	0.000764	0.00921	CcSEcCtD
Drospirenone—Skin disorder—Latanoprost—glaucoma	0.000756	0.00912	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Diclofenamide—glaucoma	0.000754	0.0091	CcSEcCtD
Drospirenone—Acute coronary syndrome—Pilocarpine—glaucoma	0.000745	0.00899	CcSEcCtD
Drospirenone—Myocardial infarction—Pilocarpine—glaucoma	0.000741	0.00894	CcSEcCtD
Drospirenone—Erythema multiforme—Acetazolamide—glaucoma	0.000741	0.00894	CcSEcCtD
Drospirenone—PGR—Ovarian Infertility Genes—CCND2—glaucoma	0.000722	0.018	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—LMX1B—glaucoma	0.000721	0.018	CbGpPWpGaD
Drospirenone—Breast disorder—Clonidine—glaucoma	0.000708	0.00854	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Methazolamide—glaucoma	0.000694	0.00837	CcSEcCtD
Drospirenone—Angiopathy—Brimonidine—glaucoma	0.000682	0.00823	CcSEcCtD
Drospirenone—Erythema multiforme—Dorzolamide—glaucoma	0.000679	0.00819	CcSEcCtD
Drospirenone—Affect lability—Betaxolol—glaucoma	0.000671	0.0081	CcSEcCtD
Drospirenone—Mental disorder—Brimonidine—glaucoma	0.000659	0.00795	CcSEcCtD
Drospirenone—Angiopathy—Travoprost—glaucoma	0.000649	0.00783	CcSEcCtD
Drospirenone—Mood swings—Betaxolol—glaucoma	0.000646	0.00779	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Apraclonidine—glaucoma	0.000645	0.00778	CcSEcCtD
Drospirenone—NR3C2—Nuclear Receptor transcription pathway—NR3C1—glaucoma	0.000643	0.016	CbGpPWpGaD
Drospirenone—Angiopathy—Brinzolamide—glaucoma	0.000641	0.00773	CcSEcCtD
Drospirenone—Mental disorder—Travoprost—glaucoma	0.000627	0.00756	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Bimatoprost—glaucoma	0.000625	0.00754	CcSEcCtD
Drospirenone—Mental disorder—Brinzolamide—glaucoma	0.000619	0.00746	CcSEcCtD
Drospirenone—Breast disorder—Betaxolol—glaucoma	0.000616	0.00743	CcSEcCtD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.000613	0.0153	CbGpPWpGaD
Drospirenone—Nervous system disorder—Apraclonidine—glaucoma	0.00061	0.00736	CcSEcCtD
Drospirenone—Skin disorder—Apraclonidine—glaucoma	0.000605	0.00729	CcSEcCtD
Drospirenone—Depression—Clonidine—glaucoma	0.000602	0.00726	CcSEcCtD
Drospirenone—Nervous system disorder—Bimatoprost—glaucoma	0.000592	0.00714	CcSEcCtD
Drospirenone—Skin disorder—Bimatoprost—glaucoma	0.000586	0.00707	CcSEcCtD
Drospirenone—Nausea—Metipranolol—glaucoma	0.00057	0.00687	CcSEcCtD
Drospirenone—Cerebrovascular accident—Timolol—glaucoma	0.000569	0.00686	CcSEcCtD
Drospirenone—Medrysone—NR3C1—glaucoma	0.000566	0.155	CrCbGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Brimonidine—glaucoma	0.000554	0.00668	CcSEcCtD
Drospirenone—Affect lability—Timolol—glaucoma	0.000549	0.00661	CcSEcCtD
Drospirenone—Flurandrenolide—NR3C1—glaucoma	0.000546	0.149	CrCbGaD
Drospirenone—Gastrointestinal disorder—Apraclonidine—glaucoma	0.000537	0.00648	CcSEcCtD
Drospirenone—Mood swings—Timolol—glaucoma	0.000528	0.00637	CcSEcCtD
Drospirenone—Nausea—Carteolol—glaucoma	0.000528	0.00636	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.000526	0.00635	CcSEcCtD
Drospirenone—Depression—Betaxolol—glaucoma	0.000524	0.00632	CcSEcCtD
Drospirenone—Nervous system disorder—Brimonidine—glaucoma	0.000524	0.00632	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Bimatoprost—glaucoma	0.000521	0.00628	CcSEcCtD
Drospirenone—Cortisone acetate—NR3C1—glaucoma	0.00052	0.142	CrCbGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.00052	0.00627	CcSEcCtD
Drospirenone—Skin disorder—Brimonidine—glaucoma	0.000519	0.00626	CcSEcCtD
Drospirenone—Nausea—Diclofenamide—glaucoma	0.000519	0.00626	CcSEcCtD
Drospirenone—Acute coronary syndrome—Betaxolol—glaucoma	0.000518	0.00625	CcSEcCtD
Drospirenone—Myocardial infarction—Betaxolol—glaucoma	0.000515	0.00621	CcSEcCtD
Drospirenone—Nausea—Carbachol—glaucoma	0.000506	0.00611	CcSEcCtD
Drospirenone—Breast disorder—Timolol—glaucoma	0.000504	0.00607	CcSEcCtD
Drospirenone—Megestrol acetate—NR3C1—glaucoma	0.000501	0.137	CrCbGaD
Drospirenone—BCHE—Peptide hormone metabolism—ACE2—glaucoma	0.000501	0.0125	CbGpPWpGaD
Drospirenone—Nausea—Levobunolol—glaucoma	0.000499	0.00601	CcSEcCtD
Drospirenone—Nervous system disorder—Travoprost—glaucoma	0.000498	0.00601	CcSEcCtD
Drospirenone—PGR—Nuclear Receptors—NR3C1—glaucoma	0.000495	0.0123	CbGpPWpGaD
Drospirenone—Skin disorder—Travoprost—glaucoma	0.000494	0.00595	CcSEcCtD
Drospirenone—Nervous system disorder—Brinzolamide—glaucoma	0.000492	0.00593	CcSEcCtD
Drospirenone—Angiopathy—Clonidine—glaucoma	0.000492	0.00593	CcSEcCtD
Drospirenone—Skin disorder—Brinzolamide—glaucoma	0.000487	0.00588	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000481	0.0058	CcSEcCtD
Drospirenone—Nausea—Methazolamide—glaucoma	0.000478	0.00576	CcSEcCtD
Drospirenone—Mental disorder—Clonidine—glaucoma	0.000475	0.00573	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Brimonidine—glaucoma	0.000461	0.00556	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Travoprost—glaucoma	0.000439	0.00529	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000433	0.00522	CcSEcCtD
Drospirenone—Depression—Timolol—glaucoma	0.000428	0.00516	CcSEcCtD
Drospirenone—Angiopathy—Betaxolol—glaucoma	0.000428	0.00516	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000416	0.00502	CcSEcCtD
Drospirenone—Mental disorder—Betaxolol—glaucoma	0.000413	0.00499	CcSEcCtD
Drospirenone—AR—FOXA1 transcription factor network—SOD1—glaucoma	0.000404	0.0101	CbGpPWpGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000399	0.00481	CcSEcCtD
Drospirenone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—glaucoma	0.000398	0.00993	CbGpPWpGaD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—SOD1—glaucoma	0.000393	0.0098	CbGpPWpGaD
Drospirenone—PGR—Nuclear Receptor transcription pathway—NR3C1—glaucoma	0.000391	0.00975	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—CA1—glaucoma	0.000391	0.00973	CbGpPWpGaD
Drospirenone—Nervous system disorder—Clonidine—glaucoma	0.000378	0.00455	CcSEcCtD
Drospirenone—AR—Nuclear Receptors—NR3C1—glaucoma	0.000377	0.0094	CbGpPWpGaD
Drospirenone—Skin disorder—Clonidine—glaucoma	0.000374	0.00451	CcSEcCtD
Drospirenone—Nausea—Apraclonidine—glaucoma	0.00037	0.00446	CcSEcCtD
Drospirenone—Nausea—Bimatoprost—glaucoma	0.000358	0.00432	CcSEcCtD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.000352	0.00878	CbGpPWpGaD
Drospirenone—Angiopathy—Timolol—glaucoma	0.00035	0.00422	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000347	0.00419	CcSEcCtD
Drospirenone—Mental disorder—Timolol—glaucoma	0.000338	0.00407	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Clonidine—glaucoma	0.000332	0.00401	CcSEcCtD
Drospirenone—Nausea—Acetazolamide—glaucoma	0.000331	0.00399	CcSEcCtD
Drospirenone—Nervous system disorder—Betaxolol—glaucoma	0.000329	0.00397	CcSEcCtD
Drospirenone—PGR—Ovarian Infertility Genes—CDKN1B—glaucoma	0.000328	0.00817	CbGpPWpGaD
Drospirenone—Skin disorder—Betaxolol—glaucoma	0.000326	0.00393	CcSEcCtD
Drospirenone—Nausea—Brimonidine—glaucoma	0.000317	0.00383	CcSEcCtD
Drospirenone—PTGS2—Overview of nanoparticle effects—FN1—glaucoma	0.000317	0.00789	CbGpPWpGaD
Drospirenone—PGR—Cellular roles of Anthrax toxin—TNF—glaucoma	0.000315	0.00786	CbGpPWpGaD
Drospirenone—PGR—Validated nuclear estrogen receptor alpha network—C3—glaucoma	0.000312	0.00777	CbGpPWpGaD
Drospirenone—Spironolactone—NR3C1—glaucoma	0.000312	0.085	CrCbGaD
Drospirenone—Nausea—Dorzolamide—glaucoma	0.000303	0.00366	CcSEcCtD
Drospirenone—Nausea—Travoprost—glaucoma	0.000302	0.00364	CcSEcCtD
Drospirenone—AR—Nuclear Receptor transcription pathway—NR3C1—glaucoma	0.000298	0.00743	CbGpPWpGaD
Drospirenone—Nausea—Brinzolamide—glaucoma	0.000298	0.00359	CcSEcCtD
Drospirenone—Medroxyprogesterone Acetate—NR3C1—glaucoma	0.000292	0.0797	CrCbGaD
Drospirenone—Gastrointestinal disorder—Betaxolol—glaucoma	0.000289	0.00349	CcSEcCtD
Drospirenone—AR—Regulation of Androgen receptor activity—NR3C1—glaucoma	0.000289	0.00721	CbGpPWpGaD
Drospirenone—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—glaucoma	0.000287	0.00714	CbGpPWpGaD
Drospirenone—Nausea—Pilocarpine—glaucoma	0.000286	0.00345	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000284	0.00342	CcSEcCtD
Drospirenone—Progesterone—CYP1B1—glaucoma	0.000284	0.0774	CrCbGaD
Drospirenone—Nervous system disorder—Timolol—glaucoma	0.000269	0.00324	CcSEcCtD
Drospirenone—Testosterone—CYP1B1—glaucoma	0.000268	0.0732	CrCbGaD
Drospirenone—BCHE—Peptide hormone metabolism—PAX6—glaucoma	0.000267	0.00666	CbGpPWpGaD
Drospirenone—Skin disorder—Timolol—glaucoma	0.000266	0.00321	CcSEcCtD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND2—glaucoma	0.000264	0.00659	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—HDAC9—glaucoma	0.000258	0.00644	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—glaucoma	0.000252	0.00627	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—TXN—glaucoma	0.000243	0.00604	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Timolol—glaucoma	0.000236	0.00285	CcSEcCtD
Drospirenone—PTGS2—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000235	0.00587	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—CDKN2B—glaucoma	0.000235	0.00585	CbGpPWpGaD
Drospirenone—Nausea—Clonidine—glaucoma	0.000229	0.00276	CcSEcCtD
Drospirenone—BCHE—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.000222	0.00554	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—C1QB—glaucoma	0.000215	0.00536	CbGpPWpGaD
Drospirenone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—glaucoma	0.000208	0.00518	CbGpPWpGaD
Drospirenone—Hydrocortisone—NR3C1—glaucoma	0.000207	0.0565	CrCbGaD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—NR3C1—glaucoma	0.000206	0.00513	CbGpPWpGaD
Drospirenone—Nausea—Betaxolol—glaucoma	0.000199	0.0024	CcSEcCtD
Drospirenone—AR—FOXA1 transcription factor network—CDKN1B—glaucoma	0.000194	0.00483	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—NTRK2—glaucoma	0.000185	0.00461	CbGpPWpGaD
Drospirenone—AR—Notch-mediated HES/HEY network—CDKN1B—glaucoma	0.000184	0.00458	CbGpPWpGaD
Drospirenone—PTGS2—S1P1 pathway—VEGFA—glaucoma	0.000181	0.00452	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	0.000172	0.00429	CbGpPWpGaD
Drospirenone—BCHE—Neuronal System—SLC6A13—glaucoma	0.00017	0.00425	CbGpPWpGaD
Drospirenone—Progesterone—NR3C1—glaucoma	0.000169	0.046	CrCbGaD
Drospirenone—AR—Coregulation of Androgen receptor activity—CDKN2A—glaucoma	0.000168	0.0042	CbGpPWpGaD
Drospirenone—AR—Androgen receptor signaling pathway—CAV1—glaucoma	0.000168	0.00419	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—DHPS—glaucoma	0.000165	0.0041	CbGpPWpGaD
Drospirenone—BCHE—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.000163	0.00406	CbGpPWpGaD
Drospirenone—Nausea—Timolol—glaucoma	0.000163	0.00196	CcSEcCtD
Drospirenone—PTGS2—Overview of nanoparticle effects—TNF—glaucoma	0.000155	0.00387	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—ABCA1—glaucoma	0.00015	0.00373	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—glaucoma	0.000148	0.00369	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—BDNF—glaucoma	0.000138	0.00344	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—glaucoma	0.000136	0.00338	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—BAD—glaucoma	0.000135	0.00337	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—SOD1—glaucoma	0.000134	0.00333	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—IL1A—glaucoma	0.000133	0.0033	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.000128	0.0032	CbGpPWpGaD
Drospirenone—NR3C2—Generic Transcription Pathway—CDKN2B—glaucoma	0.000126	0.00315	CbGpPWpGaD
Drospirenone—BCHE—Neuronal System—SLC6A1—glaucoma	0.000125	0.00311	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—GSTM1—glaucoma	0.000124	0.0031	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—NGF—glaucoma	0.000122	0.00305	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—NR3C1—glaucoma	0.000122	0.00304	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000119	0.00296	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.000118	0.00294	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.000117	0.00293	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—MMP1—glaucoma	0.000115	0.00287	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—NGFR—glaucoma	0.000114	0.00284	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—NARFL—glaucoma	0.000112	0.00279	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CA5A—glaucoma	0.000112	0.00279	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—LRP12—glaucoma	0.000112	0.00278	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—glaucoma	0.000111	0.00277	CbGpPWpGaD
Drospirenone—NR3C2—Generic Transcription Pathway—NR3C1—glaucoma	0.000111	0.00277	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—glaucoma	0.000107	0.00268	CbGpPWpGaD
Drospirenone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—glaucoma	0.000107	0.00266	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—MTHFR—glaucoma	0.000106	0.00264	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—BAD—glaucoma	0.000104	0.00258	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—CTSA—glaucoma	0.000103	0.00256	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	0.0001	0.0025	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—BDNF—glaucoma	9.92e-05	0.00247	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	9.89e-05	0.00246	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—IL1A—glaucoma	9.53e-05	0.00237	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—ACE2—glaucoma	9.46e-05	0.00236	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—CDKN1B—glaucoma	9.43e-05	0.00235	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—glaucoma	8.94e-05	0.00223	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	8.59e-05	0.00214	CbGpPWpGaD
Drospirenone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—glaucoma	8.4e-05	0.00209	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	8.19e-05	0.00204	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—OPN4—glaucoma	7.73e-05	0.00193	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CA5A—glaucoma	7.71e-05	0.00192	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NARFL—glaucoma	7.71e-05	0.00192	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—CDKN2B—glaucoma	7.7e-05	0.00192	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—TNF—glaucoma	7.66e-05	0.00191	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—CDKN2A—glaucoma	7.5e-05	0.00187	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	7.37e-05	0.00184	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—HEYL—glaucoma	7.19e-05	0.00179	CbGpPWpGaD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—glaucoma	7.17e-05	0.00179	CbGpPWpGaD
Drospirenone—PTGS2—Disease—LRP12—glaucoma	6.98e-05	0.00174	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PTGFR—glaucoma	6.96e-05	0.00173	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	6.79e-05	0.00169	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—NR3C1—glaucoma	6.76e-05	0.00168	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	6.75e-05	0.00168	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—CDKN1B—glaucoma	6.64e-05	0.00165	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	6.32e-05	0.00157	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—CDKN2B—glaucoma	6.09e-05	0.00152	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—VEGFA—glaucoma	6.01e-05	0.0015	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	5.98e-05	0.00149	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—CDKN2B—glaucoma	5.87e-05	0.00146	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—VEGFA—glaucoma	5.85e-05	0.00146	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	5.78e-05	0.00144	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CA1—glaucoma	5.47e-05	0.00136	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—RPTOR—glaucoma	5.45e-05	0.00136	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—NR3C1—glaucoma	5.34e-05	0.00133	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CTSA—glaucoma	5.3e-05	0.00132	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NCK2—glaucoma	5.27e-05	0.00131	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—NR3C1—glaucoma	5.15e-05	0.00128	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—CDKN1B—glaucoma	5.06e-05	0.00126	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—PAX6—glaucoma	5.05e-05	0.00126	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—TNF—glaucoma	5.01e-05	0.00125	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CA2—glaucoma	5e-05	0.00125	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	4.98e-05	0.00124	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	4.94e-05	0.00123	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	4.89e-05	0.00122	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	4.89e-05	0.00122	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—MMP9—glaucoma	4.68e-05	0.00117	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—TNF—glaucoma	4.56e-05	0.00114	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—TP53—glaucoma	4.54e-05	0.00113	CbGpPWpGaD
Drospirenone—PTGS2—Disease—HEYL—glaucoma	4.5e-05	0.00112	CbGpPWpGaD
Drospirenone—PTGS2—Disease—FGFR1OP—glaucoma	4.5e-05	0.00112	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—HDAC9—glaucoma	4.49e-05	0.00112	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	4.27e-05	0.00106	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CA1—glaucoma	3.77e-05	0.000938	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	3.76e-05	0.000937	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—CDKN2B—glaucoma	3.71e-05	0.000924	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CTSA—glaucoma	3.65e-05	0.000909	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—TNF—glaucoma	3.6e-05	0.000898	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—TXN—glaucoma	3.52e-05	0.000878	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—SMO—glaucoma	3.51e-05	0.000875	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CA2—glaucoma	3.44e-05	0.000858	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	3.44e-05	0.000857	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	3.37e-05	0.000839	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	3.37e-05	0.000839	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—NR3C1—glaucoma	3.26e-05	0.000811	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—APOE—glaucoma	3.22e-05	0.000802	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NTRK2—glaucoma	3.21e-05	0.0008	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—CAV1—glaucoma	3.19e-05	0.000794	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—TP53—glaucoma	3.18e-05	0.000792	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—MMP1—glaucoma	2.87e-05	0.000716	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	2.86e-05	0.000713	CbGpPWpGaD
Drospirenone—AR—Gene Expression—CDKN2B—glaucoma	2.83e-05	0.000704	CbGpPWpGaD
Drospirenone—PTGS2—Disease—HDAC9—glaucoma	2.81e-05	0.000699	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NGFR—glaucoma	2.75e-05	0.000686	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GSTT1—glaucoma	2.73e-05	0.000681	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NTRK1—glaucoma	2.62e-05	0.000652	CbGpPWpGaD
Drospirenone—AR—Gene Expression—NR3C1—glaucoma	2.48e-05	0.000618	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	2.45e-05	0.000611	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—TXN—glaucoma	2.43e-05	0.000605	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CDKN2B—glaucoma	2.41e-05	0.000601	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—EDN1—glaucoma	2.31e-05	0.000577	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—MMP2—glaucoma	2.22e-05	0.000554	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—APOE—glaucoma	2.21e-05	0.000552	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	2.2e-05	0.000549	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	2.19e-05	0.000547	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—ABCA1—glaucoma	2.18e-05	0.000543	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CYP1B1—glaucoma	2.18e-05	0.000543	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	2.16e-05	0.000539	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NGF—glaucoma	2.13e-05	0.00053	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—C3—glaucoma	2.02e-05	0.000504	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—APOE—glaucoma	1.88e-05	0.000469	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTT1—glaucoma	1.88e-05	0.000469	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CAV1—glaucoma	1.86e-05	0.000465	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—FN1—glaucoma	1.77e-05	0.000442	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—BAD—glaucoma	1.75e-05	0.000437	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GSTM1—glaucoma	1.74e-05	0.000434	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—MTHFR—glaucoma	1.54e-05	0.000383	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CDKN2B—glaucoma	1.51e-05	0.000376	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ABCA1—glaucoma	1.5e-05	0.000374	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP1B1—glaucoma	1.5e-05	0.000374	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—APOE—glaucoma	1.43e-05	0.000357	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CAV1—glaucoma	1.42e-05	0.000354	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NOS3—glaucoma	1.41e-05	0.000351	CbGpPWpGaD
Drospirenone—PTGS2—Disease—MTHFR—glaucoma	1.26e-05	0.000315	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CDKN1B—glaucoma	1.22e-05	0.000304	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTM1—glaucoma	1.2e-05	0.000299	CbGpPWpGaD
Drospirenone—PTGS2—Disease—APOE—glaucoma	1.18e-05	0.000293	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CAV1—glaucoma	1.17e-05	0.000291	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—MMP9—glaucoma	1.13e-05	0.000282	CbGpPWpGaD
Drospirenone—PTGS2—Disease—BAD—glaucoma	1.1e-05	0.000273	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—NOS3—glaucoma	1.07e-05	0.000267	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—MTHFR—glaucoma	1.06e-05	0.000264	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—VEGFA—glaucoma	1.02e-05	0.000253	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—APOE—glaucoma	9.86e-06	0.000246	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PTGS2—glaucoma	9.81e-06	0.000245	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CAV1—glaucoma	9.77e-06	0.000243	CbGpPWpGaD
Drospirenone—PTGS2—Disease—NOS3—glaucoma	8.82e-06	0.00022	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TP53—glaucoma	7.67e-06	0.000191	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CDKN1B—glaucoma	7.64e-06	0.00019	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NOS3—glaucoma	7.39e-06	0.000184	CbGpPWpGaD
